Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease
Primary Purpose
Anemia, Sickle Cell
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cogmed RM
Sponsored by
About this trial
This is an interventional treatment trial for Anemia, Sickle Cell focused on measuring Neurocognitive, Working memory, Cogmed, Cognitive training
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with sickle cell disease (HbSS, HbSC, or HbS-beta thalassemia).
- 7 to 16 years old.
- An absolute or relative working memory deficit.
- IQ of 70 or greater, as measured via the WISC-V.
- Presence of a caregiver who is willing and capable of providing consistent support and supervision during Cogmed training.
Exclusion Criteria:
- Visual, motor, or auditory impairment that prevents computer use.
- Insufficient English fluency.
- Started taking or adjusted dose of medication to treat symptoms of ADHD in the last 30 days.
- Unreliable access to a source of electricity to charge an iPad battery.
Sites / Locations
- Children's National Health System
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Cogmed intervention
Cogmed-waitlist control
Arm Description
Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
Outcomes
Primary Outcome Measures
Cogmed feasibility assessed by program completion rates
Feasibility will be determined by examining the proportion of the sample that completes at least 20 Cogmed sessions (i.e., 80% of the program) within the allotted time frame (10-week maximum).
Secondary Outcome Measures
Verbal working memory assessed by change in Wechsler Intelligence Scale for Children (WISC-V) Digit Span subtest
Cogmed efficacy will be evaluated by examining change in scaled scores on the WISC-V Digit Span subtest after completing Cogmed.
Visua-spatial working memory assessed by change in Wechsler Intelligence Scale for Children (WISC-V) Picture Span subtest
Cogmed efficacy will be evaluated by examining change in scaled scores on the WISC-V Picture Span subtest after completing Cogmed.
Visua-spatial working memory assessed by change in Wechsler Intelligence Scale for Children (WISC-V) Spatial Span subtest
Cogmed efficacy will be evaluated by examining change in scaled scores on the WISC-V Spatial Span subtest after completing Cogmed.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02857023
Brief Title
Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease
Official Title
Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
October 2014 (Actual)
Primary Completion Date
July 2018 (Actual)
Study Completion Date
August 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Steven J. Hardy
4. Oversight
5. Study Description
Brief Summary
Disease-related neurocognitive deficits are common in pediatric sickle cell disease (SCD). These deficits can significantly disrupt otherwise normal trajectories toward academic and vocational achievement and negatively impact psychosocial outcomes. Despite widespread recognition of neurocognitive deficits, there are no treatments shown to maintain or recover functioning once a child with SCD endures neuronal damage. Cognitive training (CT) has been a standard intervention used to stabilize and recover functioning in individuals with accidental or disease-related brain injury. Recent advances in technology have led to the development of computerized CT programs. This study seeks to assess the feasibility and efficacy of using computerized CT with pediatric patients with SCD. Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed). Feasibility will be assessed by examining participation, retention, and program completion rates, as well as feedback from a feasibility and acceptability questionnaire and a brief qualitative interview. Participants will also complete assessments of attention, working memory, and academic fluency at baseline and immediately following the intervention. A final assessment will be conducted 6 months after the conclusion of the intervention to evaluate the stability of treatment effects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anemia, Sickle Cell
Keywords
Neurocognitive, Working memory, Cogmed, Cognitive training
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
91 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cogmed intervention
Arm Type
Experimental
Arm Description
Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
Arm Title
Cogmed-waitlist control
Arm Type
Experimental
Arm Description
Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
Intervention Type
Behavioral
Intervention Name(s)
Cogmed RM
Intervention Description
Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
Primary Outcome Measure Information:
Title
Cogmed feasibility assessed by program completion rates
Description
Feasibility will be determined by examining the proportion of the sample that completes at least 20 Cogmed sessions (i.e., 80% of the program) within the allotted time frame (10-week maximum).
Time Frame
Following completion of Cogmed (approximately 8-10 weeks from baseline)
Secondary Outcome Measure Information:
Title
Verbal working memory assessed by change in Wechsler Intelligence Scale for Children (WISC-V) Digit Span subtest
Description
Cogmed efficacy will be evaluated by examining change in scaled scores on the WISC-V Digit Span subtest after completing Cogmed.
Time Frame
Baseline, 8-10 weeks, 6-month follow-up
Title
Visua-spatial working memory assessed by change in Wechsler Intelligence Scale for Children (WISC-V) Picture Span subtest
Description
Cogmed efficacy will be evaluated by examining change in scaled scores on the WISC-V Picture Span subtest after completing Cogmed.
Time Frame
Baseline, 8-10 weeks, 6-month follow-up
Title
Visua-spatial working memory assessed by change in Wechsler Intelligence Scale for Children (WISC-V) Spatial Span subtest
Description
Cogmed efficacy will be evaluated by examining change in scaled scores on the WISC-V Spatial Span subtest after completing Cogmed.
Time Frame
Baseline, 8-10 weeks, 6-month follow-up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with sickle cell disease (HbSS, HbSC, or HbS-beta thalassemia).
7 to 16 years old.
An absolute or relative working memory deficit.
IQ of 70 or greater, as measured via the WISC-V.
Presence of a caregiver who is willing and capable of providing consistent support and supervision during Cogmed training.
Exclusion Criteria:
Visual, motor, or auditory impairment that prevents computer use.
Insufficient English fluency.
Started taking or adjusted dose of medication to treat symptoms of ADHD in the last 30 days.
Unreliable access to a source of electricity to charge an iPad battery.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Hardy, PhD
Organizational Affiliation
Children's National Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's National Health System
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease
We'll reach out to this number within 24 hrs